Effect of Huobahuagen Tablets on chronic kidney disease
Objective To study the efficacy of Huobahuagen Tablets in the treatment of chronic kidney disease and its impact on urine protein,liver and kidney function and blood lipids etc in patients.Methods A retrospective Cohort study was performed to analyze the data of 100 patients with chronic kidney disease admitted to our hospital from June 2022 to April 2023.According to the treatment regime,the patients were divided into control group and study group,each with 50 cases.The control group only received conventional treatment,while the study group additionally received Huobahuagen Tablets.The levels of total urinary protein(UTP)in 24 hours,the liver and kidney function indicators[serum albumin(ALB),glutamic pyruvic transaminase(GPT),serum creatinine(Scr),and endogenous creatinine clearance rate(CCr)],the blood lipids[triacylglycerol(TG),total cholesterol(TC),high-density lipoprotein(HDL-C),and low-density lipoprotein(LDL-C)],and the immune function indicators[T lymphocyte subsets(CD4+,CD8+,and CD4+/CD8+)]were compared between the 2 groups before and after treatment,and the efficacy and incidence of adverse reactions were also compared.Results After treatment,compared with the control group,the UTP levels[(1.22±0.21)g·24 h-1 vs.(2.36±0.31)g·24 h-1]and Scr levels[(107.98±10.14)μmol·L-1 vs.(123.42±12.31)μmol·L-1]of the study group decreased,while the ALB levels[(46.98±5.64)g·L-1 vs.(43.62±3.41)g·L-1],and CCr levels[(49.98±6.57)mL·min-1 vs.(42.13±4.35)mL·min-1]increased,with statistically significant differences(t=21.530,6.846,8.125,3.605,7.045,all P＜0.05).After treatment,the GPT of the study group were slightly lower than those of the control group,but the difference was not statistically significant(P＞0.05).After treatment,compared with the control group,the TG[(1.43±0.21)mmol·L-1 vs.(2.00±0.25)mmol·L-1],the TC[(4.72±0.35)mmol·L-1 vs.(5.08±0.40)mmol·L-1],and the LDL-C[(3.01±0.14)mmol·L-1 vs.(3.26±0.17)mmol·L-1]of the study group were lower,while the HDL-C[(1.69±0.35)mmol·L-1 vs.(1.40±0.22)mmol·L-1]was higher with significant difference(t=12.340,4.789,8.027,4.960,all P＜0.05).The proportion of CD4+[(44.53％±5.16％)vs.(40.21％±4.35％)],and the CD4+/CD8+ratio[(1.78±0.31)vs.(1.36±0.24)]of the study group increased,while the CD8+ratio[(24.36％±2.15％)vs.(28.98％±2.21％)]decreased with significant difference(t=4.526,7.575,10.600,P＜0.05).Compared with the control group,the total effective rate of the study group was higher(96.00％vs.82.00％),and the difference was statistically significant(x2=5.005,P＜0.05).There was no significant difference in the incidence of adverse reactions between the 2 groups(P＞0.05).Conclusion Huohuagen Tablets can reduce the level of urinary protein,improve immune function,improve lipid metabolism,promote the recovery of renal function in patients with chronic kidney disease,and do not cause liver function damage.The tablets are effective and safety.
Huobahuagen Tabletschronic kidney diseaseurinary proteinliver and kidney functionlipid metabolismimmune inflammationpodocyte
NETL
NSTL
万方数据
